Literature DB >> 10570080

Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation.

B D Maes, Y F Vanrenterghem.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570080     DOI: 10.1093/ndt/14.12.2824

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  5 in total

1.  Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.

Authors:  G Van Assche; W J Sandborn; B G Feagan; B A Salzberg; D Silvers; P S Monroe; W M Pandak; F H Anderson; J F Valentine; G E Wild; D J Geenen; R Sprague; S R Targan; P Rutgeerts; V Vexler; D Young; R S Shames
Journal:  Gut       Date:  2006-04-07       Impact factor: 23.059

Review 2.  Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.

Authors:  Agnieszka Swiatecka-Urban
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Basiliximab induced non-cardiogenic pulmonary edema in two pediatric renal transplant recipients.

Authors:  Niamh Dolan; Mary Waldron; Marie O'Connell; Nick Eustace; Kevin Carson; Atif Awan
Journal:  Pediatr Nephrol       Date:  2009-08-01       Impact factor: 3.714

4.  Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study.

Authors:  Hussein A Sheashaa; Mohamed A Bakr; Amani M Ismail; Khaled M Mahmoud; Mohamed A Sobh; Mohamed A Ghoneim
Journal:  Clin Exp Nephrol       Date:  2008-03-11       Impact factor: 2.801

5.  Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation.

Authors:  Maciej Nowacki; Łukasz Nazarewski; Tomasz Kloskowski; Dominik Tyloch; Marta Pokrywczyńska; Katarzyna Pietkun; Arkadiusz Jundziłł; Janusz Tyloch; Samy L Habib; Tomasz Drewa
Journal:  Arch Med Sci       Date:  2016-08-25       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.